CN101223166A - 噻唑基mglur5拮抗剂及其应用方法 - Google Patents
噻唑基mglur5拮抗剂及其应用方法 Download PDFInfo
- Publication number
- CN101223166A CN101223166A CNA2005800415189A CN200580041518A CN101223166A CN 101223166 A CN101223166 A CN 101223166A CN A2005800415189 A CNA2005800415189 A CN A2005800415189A CN 200580041518 A CN200580041518 A CN 200580041518A CN 101223166 A CN101223166 A CN 101223166A
- Authority
- CN
- China
- Prior art keywords
- ethynyl
- thiazole
- methyl isophthalic
- compound
- isophthalic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Description
实施例 | 钙流动测定(nM) | Ki(nM) |
1 | 3 | 20 |
2 | 1.0 | 2.0 |
3 | 0.9 | 2.7 |
4 | 2.2 | 2.6 |
5 | 6.3 | 1.0 |
6 | 4.4 | 1.2 |
7 | 1.1 | 0.7 |
8 | 1.0 | 0.9 |
9 | 1.1 | N.D. |
10 | 0.7 | N.D. |
11 | 1.3 | N.D. |
12 | 0.6 | 1.1 |
13 | 0.6 | 0.6 |
14 | 0.8 | 7.5 |
15 | 1.0 | 2.6 |
16 | 0.4 | 8.6 |
17 | 0.4 | 3.8 |
18 | 4.9 | 19.3 |
19 | 1.8 | 2.8 |
20 | 1.0 | 1.4 |
21 | 1.5 | 1.5 |
22 | 1.2 | 0.9 |
23 | 1.6 | 1.6 |
24 | 0.3 | 2.6 |
25 | 1.4 | 9.0 |
26 | 0.1 | 2.0 |
27 | 1.4 | 1.0 |
28 | 1.7 | 0.9 |
29 | 0.5 | 10 |
30 | 2.2 | 2.3 |
31 | 2.9 | 12.2 |
32 | 1.0 | 4.8 |
33 | 19 | 7 |
34 | 18 | 15 |
35 | 17 | 5 |
36 | 14 | 3 |
37 | 14 | 10 |
38 | 13 | 8 |
39 | 13 | 4 |
40 | 12 | 9 |
41 | 11 | 5 |
42 | 11 | 17 |
43 | 11 | 0.65 |
44 | 11 | 2 |
45 | 11 | 7 |
46 | 11 | 2 |
47 | 11 | 19 |
48 | 9 | 12.5 |
49 | 9 | 5.5 |
50 | 9 | 12 |
51 | 8 | 9 |
52 | 8 | 2 |
53 | 8 | 8 |
54 | 8 | 1.5 |
55 | 7 | 4 |
56 | 7 | 13 |
57 | 7 | 7.5 |
58 | 7 | 1.5 |
59 | 6 | 4 |
60 | 6 | 1.5 |
61 | 6 | 12 |
62 | 6 | 11 |
63 | 6 | 4 |
64 | 6 | 0.8 |
65 | 6 | 8 |
66 | 5 | 9 |
67 | 5 | 7 |
68 | 5 | 7 |
69 | 5 | 14 |
70 | 5 | 5 |
71 | 5 | 4.5 |
72 | 5 | 7 |
73 | 4 | 2 |
74 | 4 | 7.5 |
75 | 4 | 4 |
76 | 3.5 | 3 |
77 | 3 | 13 |
78 | 3 | 1.4 |
79 | 3 | 16 |
80 | 3 | 3 |
81 | 3 | 6 |
82 | 3 | 2 |
83 | 2 | 12 |
84 | 2 | 7 |
85 | 2 | 1 |
86 | 2 | 7 |
87 | 2 | N.D. |
88 | 2 | 4 |
89 | 1.6 | 2 |
90 | 1.5 | 4 |
91 | 1 | 1 |
92 | 12 | 7 |
93 | 11 | 3 |
94 | 9 | 6 |
95 | 8 | 9 |
96 | 5 | 5 |
97 | 5 | 13 |
98 | 4 | 8 |
99 | 2.8 | 33 |
100 | 2.3 | 23 |
101 | 2 | 24 |
102 | 2 | 26 |
103 | 1.6 | 1.6 |
104 | 1.5 | 6 |
105 | 1 | 1 |
106 | N.D. | 6 |
107 | 16 | 9 |
Claims (4)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61680504P | 2004-10-07 | 2004-10-07 | |
US60/616,805 | 2004-10-07 | ||
PCT/US2005/035921 WO2007050050A2 (en) | 2004-10-07 | 2005-10-06 | Thiazolyl mglur5 antagonists and methods for their use |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101223166A true CN101223166A (zh) | 2008-07-16 |
CN101223166B CN101223166B (zh) | 2011-10-19 |
Family
ID=37968242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005800415189A Active CN101223166B (zh) | 2004-10-07 | 2005-10-06 | 噻唑基mglur5拮抗剂及其应用方法 |
Country Status (9)
Country | Link |
---|---|
US (3) | US7879882B2 (zh) |
EP (2) | EP2380889B1 (zh) |
JP (2) | JP5635727B2 (zh) |
CN (1) | CN101223166B (zh) |
AT (1) | ATE520692T1 (zh) |
AU (1) | AU2005336513B2 (zh) |
CA (1) | CA2583572C (zh) |
ES (1) | ES2369783T3 (zh) |
WO (1) | WO2007050050A2 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102573493A (zh) * | 2009-10-20 | 2012-07-11 | H.隆德贝克有限公司 | 2-取代的乙炔基噻唑衍生物和其用途 |
WO2015188368A1 (en) * | 2014-06-13 | 2015-12-17 | Merck Sharp & Dohme Corp. | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles |
CN105358543A (zh) * | 2013-07-08 | 2016-02-24 | 豪夫迈·罗氏有限公司 | 作为代谢型谷氨酸受体拮抗剂的乙炔基衍生物 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2380889B1 (en) | 2004-10-07 | 2013-06-26 | Merck Sharp & Dohme Corp. | Thiazolyl MGLUR5 antagonists and methods for their use |
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
AR080055A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1 |
WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
JP5748777B2 (ja) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Crf受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
US8772300B2 (en) * | 2011-04-19 | 2014-07-08 | Hoffmann-La Roche Inc. | Phenyl or pyridinyl-ethynyl derivatives |
EP2702050B1 (en) * | 2011-04-26 | 2016-05-18 | F.Hoffmann-La Roche Ag | Pyrazolidin-3-one derivatives |
HUE025031T2 (en) * | 2011-04-26 | 2016-02-29 | Hoffmann La Roche | Ethinyl derivatives as positive allosteric modulators of MGLUR5 |
WO2014121883A1 (en) | 2013-02-07 | 2014-08-14 | Merck Patent Gmbh | Substituted acetylene derivatives and their use as positive allosteric modulators of mglur4 |
CN107849006B (zh) | 2015-06-03 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 乙炔基衍生物 |
SG10202002990XA (en) | 2017-08-04 | 2020-05-28 | Skyhawk Therapeutics Inc | Methods and compositions for modulating splicing |
CN114007613A (zh) | 2019-02-05 | 2022-02-01 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
EP3920928A4 (en) | 2019-02-06 | 2022-09-28 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6956049B1 (en) * | 1999-08-31 | 2005-10-18 | Merck & Co., Inc. | Methods of modulating processes mediated by excitatory amino acid receptors |
US7462619B2 (en) * | 1999-08-31 | 2008-12-09 | Merck & Co., Inc. | Pyridazine, pyrimidine and pyrazine ethyne compounds |
US7365074B2 (en) * | 1999-08-31 | 2008-04-29 | Merck & Co., Inc. | Pyridazine, pyrimidine and pyrazine ethyne compounds |
US6774138B2 (en) | 1999-08-31 | 2004-08-10 | Merck & Co., Inc. | Thiazolyl(pyridyl)ethyne compounds |
CA2383524C (en) * | 1999-08-31 | 2010-09-28 | Merck & Co., Inc. | Thiazolyl alkynyl compounds and methods of use thereof |
US6551270B1 (en) | 2000-08-30 | 2003-04-22 | Snowden Pencer, Inc. | Dual lumen access port |
US6903005B1 (en) | 2000-08-30 | 2005-06-07 | Micron Technology, Inc. | Method for the formation of RuSixOy-containing barrier layers for high-k dielectrics |
CA2503245A1 (en) * | 2002-10-24 | 2004-05-06 | Merck & Co., Inc. | Alkyne derivatives as tracers for metabotropic glutamate receptor binding |
EP2380889B1 (en) | 2004-10-07 | 2013-06-26 | Merck Sharp & Dohme Corp. | Thiazolyl MGLUR5 antagonists and methods for their use |
-
2005
- 2005-10-06 EP EP11167527.8A patent/EP2380889B1/en active Active
- 2005-10-06 EP EP05858618A patent/EP1893608B1/en active Active
- 2005-10-06 CA CA2583572A patent/CA2583572C/en active Active
- 2005-10-06 CN CN2005800415189A patent/CN101223166B/zh active Active
- 2005-10-06 AT AT05858618T patent/ATE520692T1/de not_active IP Right Cessation
- 2005-10-06 WO PCT/US2005/035921 patent/WO2007050050A2/en active Application Filing
- 2005-10-06 US US11/664,902 patent/US7879882B2/en active Active
- 2005-10-06 AU AU2005336513A patent/AU2005336513B2/en not_active Ceased
- 2005-10-06 ES ES05858618T patent/ES2369783T3/es active Active
- 2005-10-06 JP JP2007543041A patent/JP5635727B2/ja active Active
-
2011
- 2011-01-28 US US13/016,304 patent/US8242143B2/en active Active
-
2012
- 2012-07-26 US US13/558,537 patent/US8609852B2/en active Active
-
2014
- 2014-09-10 JP JP2014184615A patent/JP2015013885A/ja active Pending
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102573493A (zh) * | 2009-10-20 | 2012-07-11 | H.隆德贝克有限公司 | 2-取代的乙炔基噻唑衍生物和其用途 |
CN105358543A (zh) * | 2013-07-08 | 2016-02-24 | 豪夫迈·罗氏有限公司 | 作为代谢型谷氨酸受体拮抗剂的乙炔基衍生物 |
CN105358543B (zh) * | 2013-07-08 | 2018-06-12 | 豪夫迈·罗氏有限公司 | 作为代谢型谷氨酸受体拮抗剂的乙炔基衍生物 |
WO2015188368A1 (en) * | 2014-06-13 | 2015-12-17 | Merck Sharp & Dohme Corp. | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles |
US9808542B2 (en) | 2014-06-13 | 2017-11-07 | Merck Sharp & Dohme Corp. | Pyrrolo[2,3-C]pyridines as imaging agents for neurofibrillary |
US10022461B2 (en) | 2014-06-13 | 2018-07-17 | Merck Sharp & Dohme Corp. | Pyrrolo[2,3-C]pyridines as imaging agents for neurofibrilary tangles |
Also Published As
Publication number | Publication date |
---|---|
EP2380889A3 (en) | 2012-01-18 |
ES2369783T3 (es) | 2011-12-05 |
US8242143B2 (en) | 2012-08-14 |
CN101223166B (zh) | 2011-10-19 |
AU2005336513A1 (en) | 2007-05-17 |
CA2583572A1 (en) | 2006-04-07 |
WO2007050050A2 (en) | 2007-05-03 |
AU2005336513B2 (en) | 2012-08-09 |
JP2015013885A (ja) | 2015-01-22 |
US20120289696A1 (en) | 2012-11-15 |
US7879882B2 (en) | 2011-02-01 |
WO2007050050A3 (en) | 2008-02-07 |
JP2008516004A (ja) | 2008-05-15 |
EP2380889B1 (en) | 2013-06-26 |
CA2583572C (en) | 2016-07-12 |
JP5635727B2 (ja) | 2014-12-03 |
EP1893608A2 (en) | 2008-03-05 |
EP1893608A4 (en) | 2009-04-22 |
EP2380889A2 (en) | 2011-10-26 |
US8609852B2 (en) | 2013-12-17 |
AU2005336513A8 (en) | 2009-01-08 |
ATE520692T1 (de) | 2011-09-15 |
EP1893608B1 (en) | 2011-08-17 |
US20110230526A1 (en) | 2011-09-22 |
US20090203903A1 (en) | 2009-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101223166B (zh) | 噻唑基mglur5拮抗剂及其应用方法 | |
CN102977086B (zh) | 噁二唑衍生物配体及其作为亲代谢性谷氨酸受体增效剂842的用途 | |
CN100473647C (zh) | 哒嗪酮和三嗪酮化合物及其作为药物制剂的用途 | |
CN102574842B (zh) | 用于抑制pi3激酶的吡啶基咪唑酮衍生物 | |
CN103958497A (zh) | 作为AXL和c-MET激酶抑制剂的尿嘧啶衍生物 | |
CN101605792A (zh) | 氮杂-异吲哚酮和它们作为亲代谢性谷氨酸受体增效剂-613的用途 | |
CN101948425A (zh) | 作为糖皮质激素配体的化合物、包含它们的药物组合物、试剂盒及其制备方法 | |
CN101547909A (zh) | 糖皮质激素模拟物、其制备方法、药物组合物及其用途 | |
CN103649056A (zh) | 作为离子通道调节剂的稠合杂环化合物 | |
TW200908983A (en) | Heterocyclic compounds and uses thereof | |
JP2010531848A (ja) | オレキシン受容体アンタゴニストとして有用なピペリジン誘導体 | |
CN104870441A (zh) | 双环杂环化合物及其治疗用途 | |
TW201211010A (en) | Novel heterocyclic derivative and pharmaceutical composition comprising the same | |
JP2010531849A (ja) | オレキシン受容体アンタゴニストとしてのイミダゾ[1,2−c]ピリミジン−2−イルメチルピペリジン誘導体 | |
JP2003012653A (ja) | キナゾリン誘導体 | |
WO2005056532A1 (en) | Indazole derivatives which interact with the g-protein coupled receptor family | |
GB2572526A (en) | Heterocyclic small molecule modulators of human STING | |
CN116438174A (zh) | 化合物及其作为mif抑制剂的用途 | |
US20230056497A1 (en) | CD206 Modulators Their Use and Methods for Preparation | |
CN101486683B (zh) | 哒嗪酮和三嗪酮化合物及其作为药物制剂的用途 | |
AU2012208981A1 (en) | Thiazolyl mGluR5 antagonists and methods for their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SCHERING CORP (US) Free format text: FORMER OWNER: MSD CORP. Effective date: 20121030 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: MSD CORP. Free format text: FORMER NAME: SCHERING CORP (US) |
|
CP01 | Change in the name or title of a patent holder |
Address after: New jersey, USA Patentee after: MERCK SHARP & DOHME Corp. Address before: New jersey, USA Patentee before: SCHERING Corp. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20121030 Address after: New jersey, USA Patentee after: SCHERING Corp. Address before: New jersey, USA Patentee before: MERCK SHARP & DOHME Corp. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20220901 Address after: new jersey Patentee after: MERCK SHARP & DOHME B.V. Address before: new jersey Patentee before: MERCK SHARP & DOHME Corp. |
|
TR01 | Transfer of patent right |